Drug name - Dexilant Solutab

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(4 months from now)

CN1150186C TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

CN1355798A TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

EP1977751A1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1977751B1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1129088A2 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

EP1129088B1 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal Jul, 2023

(9 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 15 days from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form Jul, 2026

(3 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules Jan, 2028

(5 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules Jul, 2028

(5 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation Mar, 2029

(6 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.